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Background: The prevalence of chronic constipation is about 15 % in Western countries with a significant impact on
quality of life and health care costs. The first-line therapy, based on medical treatment combined with laxatives and
dietary rules, is often disappointing. Interferential therapy is a new treatment that has demonstrated its efficiency in the
treatment of chronic constipation in children and encouraging results in adults. The primary objective of this study is to
assess the efficacy of interferential therapy during 8 weeks in adult patients. The secondary objectives are to assess this
new and noninvasive therapy in terms of persistence of the clinical efficacy, colonic transit time, ano-rectal manometry,
patient satisfaction and quality of life (QoL), and tolerance.
Methods/Design: Design: multicenter, prospective, randomized, placebo-controlled, double blind, two-parallel groups
study. Setting: nine French adult gastroenterology centers. Inclusion criteria: adult patients with a history of chronic
constipation refractory to medical treatment for at least 3 months. Treatment groups: (1) interferential-experimental
group (effective stimulation); (2) placebo-control group (sham stimulation). Randomization: 1:1 allocation ratio. Evaluation
times: inclusion (T0, randomization), baseline assessment (T1), start of stimulation (T2), intermediary assessment
(T3, 4 weeks), end of stimulation (T4, 8 weeks), follow-up (T5 and T6, 1- and 6-month). Endpoints: (1) primary:
short-term efficacy at T4 (treatment response defined as three or more spontaneous, complete bowel movements per
week); (2) secondary: efficacy at T5 and T6, symptoms (Patient Assessment of Constipation Symptoms questionnaire),
colonic transit time, anorectal manometry, patient satisfaction (analogical visual scale), patient QoL (Patient Assessment
of Constipation Quality of Life Questionnaire), side/unexpected effects. Sample size: 200 individuals to obtain 80 %
power to detect a 20 % difference in treatment response at T4 between the two groups (15 % of lost to follow-up
patients expected).
Discussion: The randomized, double-blind, placebo-controlled design is the most appropriate to demonstrate
the efficacy of a new experimental therapeutic (Evidence-Based Medicine Working Group classification). National
and international recommendations could be updated based on the findings of this study.
Trial registration: Current controlled trials NCT02381665 (registration date: February 13, 2015).
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The prevalence of chronic constipation is about 15 %
in Western countries with a significant impact on
quality of life and health care costs [1]. Two subtypes
of constipation can be identified: slow transit constipa-
tion (STC), characterized by impaired propulsion of
stool and due to dysfunction of colonic smooth muscle
(myopathy) or its innervation (neuropathy), or both;
and evacuation disorders, characterized by difficulty or
inability with stool expulsion. They include disorders
of the anorectal function, such as dyssynergic
defecation, as well as structural disorders, such as
rectocele, descending perineum syndrome and rectal
prolapse [2]. In case of failure, few treatment options
are currently available. Surgery can sometimes be
discussed for intractable chronic constipation. In-
deed, sub-total colectomy can be proposed in case
of STC but is associated with a significant morbid-
ity. In case of pelvic floor disorders, a specific surgi-
cal treatment can be indicated. However, surgery is
invasive and has a significant morbidity, and the re-
sults are inconsistent. Recently, some studies have
assessed the efficacy of sacral neuromodulation in
the treatment of chronic constipation with some
success, but this technique is expensive and requires
the surgical implantation of a medical device [3].
More recent works, including a randomized trial, have
shown the efficacy of interferential current stimulation
in the treatment of chronic transit constipation in chil-
dren [4–6]. This treatment is used daily, at home, and
uses four adhesive surface electrodes, two abdominal
(placed below the costal margin) and two paraspinal
(placed between T9 and L2), producing two sinusoidal
currents crossing the body, 1 h per day for 1–3
months.
To date, only one open-label study has evaluated this
technique in adults and has shown encouraging results
in 3 months with an efficiency in 7/11 patients (63.6 %)
in the number of stools, severity score of constipation
and quality of life score associated with a significant
improvement in the colonic transit time measured by
radiomarkers [7]. These data are of particular interest
since laxative treatments are often disappointing, are
expensive and may have adverse events.
These observations prompted us to establish a multi-
center, prospective, two-group, placebo-controlled,
double-blind, randomized study with the primary ob-
jective of assessing the efficacy of interferential therapy
during 8 weeks in adult patients with severe chronic
constipation. The secondary objectives are to assess
this new noninvasive therapy in terms of persistence of
the efficacy, colonic transit time, ano-rectal manom-
etry, patient satisfaction and quality of life (QoL), and
tolerance.Methods/Design
Design
This multicenter, prospective, randomized, placebo-
controlled, double-blind, two-parallel group study is
performed to assess the efficacy of the use of interfer-
ential therapy: the experimental group (effective stimu-
lation) and control group (sham stimulation). The
study protocol was designed using the recommenda-
tions of the Consolidated Standards of Reporting Trials
(CONSORT) statement.
Partners
The sponsor of the study is the Assistance Publique-
Hôpitaux de Marseille (AP-HM, France). The recruit-
ing will be performed in nine French adult gastroenter-
ology departments. The methodological support will
be provided by the Clinical Research Unit (Unité Aide
Méthodologique à la Recherche Clinique, AP-HM,
France), the Clinical Investigation Unit (Centre d’Investi-
gation Clinique, AP-HM, France) and the Self-perceived
Health Assessment Research Unit (Aix-Marseille Univer-
sity, Marseille, France). The central pharmacy of AP-HM
is in charge of the assignment, allocation and delivery
of the devices. This work is supported by institutional
grants from the French 2013 National Program of Clin-
ical Research (Programme Hospitalier de Recherche
Clinique National). All the details are provided in
Table 1.
Participants
The details of the inclusion and exclusion criteria are
provided in ‘List of selection criteria’. The main inclu-
sion criteria are adult patients with a history of medical
therapy-refractory chronic constipation for more than
6 months, defined as two or fewer spontaneous,
complete bowel movements per week for a minimum
of 6 months or as a sensation of incomplete evacuation
or straining during defecation. The main exclusion cri-
teria are patients with constipation secondary to ano-
rectal malformations, to colorectal or anal organic
lesions or to a pelvic floor disorder, to a drug, to
neurologic, endocrine or metabolic disorders.
List of selection criteria
Inclusion criteria
– Adults patients (≥18 years of age) of either sex
– Subjects with a history of chronic constipation defined
as: two or fewer spontaneous, complete bowel movements
per week for a minimum of 6 months before the
screening visit or as a sensation of incomplete evacuation
or straining during defecation with at least 25 % bowel
movements
– Subjects with chronic constipation lasting for
more than 6 months
Table 1 French partners
Gastrointestinal specialists Center/department
Pr. Véronique Vitton Coordinating investigator. Public Academic Teaching Hospital Nord, Marseille
Dr. Alban Benezech Associated investigator. Public Academic Teaching Hospital Nord, Marseille
Drs. Benoit Coffin and Jean-Marc Sabate Public Academic Teaching Hospital Louis Mourrier, Paris
Dr. Henri Damon and Pr. François Mion Public Academic Teaching Hospital Hospices Civils, Lyon
Pr. Michel Dapoigny Public Academic Teaching Hospital, Clermont-Ferrand
Pr. Anne-Marie Leroi and Dr. Guillaume Gourcerol Public Academic Teaching Hospital, Rouen
Pr. Thierry Piche Public Academic Teaching Hospital, Nice
Dr. Michel Queralto Clinique des Cèdres, Cornebarrieu
Pr. Laurent Siproudhis Public Academic Teaching Hospital, Rennes
Pr. Frank Zerbib Public Academic Teaching Hospital, Bordeaux
Multidisciplinary team
Pr. Pascal Auquier Public Health, Public Academic Teaching Hospital, Marseille
Dr. Karine Baumstarck Clinical Research Unit, Public Academic Teaching Hospital, Marseille
Dr. Nathalie Lesavre Clinical Investigation Center, Public Academic Teaching Hospital, Marseille
Drs. Stéphane Honoré and Anita Cohen Pôle Pharmacie, Public Academic Teaching Hospital, Marseille
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treatment for at least 3 months (failure or intolerance of
medical treatment)
– Subjects have to interrupt any laxative treatment but
during the study, patients are allowed, in case of
absence of bowel movements for 3 or more consecutive
days, to take up 15 mg of bisacodyl (Dulcolax,
Boerhinger Ingelheim) as rescue medication
– Subjects affiliated to or beneficiary of a social security
system
– Subjects who have signed written informed consent
Exclusion criteria
– Minors or pregnant or breast-feeding women
– Subjects with chronic constipation secondary to
anorectal malformations, to colorectal or anal
organic lesions or to a pelvic floor disorder
considered by the investigator as necessitating
a surgical treatment (rectal prolapse exteriorized,
rectocele, enterocele)
– Subjects with current implanted cardiac
pacemakers, defibrillators, cardiac pumps, spinal
stimulators or other implanted electronic devices
– Subjects with chronic constipation secondary to a
drug, to neurologic, endocrine or metabolic disorders
– Subjects with a history of partial colectomy
– Subjects with megacolon, megarectum, colonic
inertia
– Subjects with skin lesions preventing the installation
of the electrodes
– Women without effective contraception (hormonal
or intrauterine device)– Subjects misunderstanding the written and spoken
French language
– Subjects participating in another biomedical research
protocolTreatments
The device procedure (effective or sham) will be blinded;
neither the patient nor the physician responsible for the
prescription will be informed of the nature of the device.
Whatever the group (control or experimental), the pa-
tients will follow the same procedure, will receive a de-
vice looking exactly the same and will have the same
follow-up. This design has already been used in ran-
domized studies using electrical stimulation [4, 8]. The
practitioner that will give the instructions concerning
the use of the device will be aware of the sham or effect-
ive stimulation since he/she will need to give different
instructions according to the device (sham or effective).
The feasibility of this treatment has previously been
demonstrated [7].Interferential-experimental group: effective stimulation
The patients will receive stimulation 1 h per day every
day at home during 8 weeks. There is no “dose adjust-
ment;” if the stimulation is not well tolerated, it will be
stopped according to the opinion of the practitioner.
The stopping criteria are as follows: severe pain or
neurological symptoms (paresthesia, burning, shaking).
Unblinding of treatment could be done by contacting
the coordinating investigator.
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The patients will receive the sham device without any
stimulation 1 h per day every day at home for 8 weeks.
The device will be the same as the one used in the ex-
perimental group but there will not be any stimulation.
The device will not be active in this group; thus, no side
effects or intolerance is expected. However, if any side
effects are reported (e.g., pain), the stimulation will be
stopped in accordance with the cessation criteria de-
tailed below. Unblinding of treatment could be made as
described above.Concomitant permitted and prohibited medications
In case of absence of bowel movements for 3 or more con-
secutive days, the patients are allowed to take up 15 mg of
Bisacodyl (Dulcolax, Boerhinger Ingelheim) as rescue medi-
cation because it is simple to use and has satisfactory toler-
ance and rapid action [9]. All other laxative drugs are
forbidden during the study.Medical device
The interferential therapy device uses a 6-V battery-
operated interferential stimulating machine (Flexitim IF
Tenscare, Fuji Dynamics, Hong Kong, CE mark 0473, Mar-
ket authorization December 2009). The device is marketed
in France by A-Legrand Co. (http://www.a-legrand.com).
Interferential treatment delivers a 4-kHz carrier frequency,
a beat frequency of 80–160 Hz and an intensity of less than
33 mA. The stimulation will be done according to the pro-
cedure described by Ismail et al. [6]. This technique uses
four adhesive surface electrodes, two abdominal (placed
below the costal margin) and two paraspinal (placed
between T9 and L2), producing two sinusoidal currents
crossing the body. To ensure the proper placement of
the electrodes, the first stimulation must be made in
the presence of the practitioner. During the 8-week
treatment period, the stimulation protocol is home-based
and self-applied by the patient for 1 h per day every day.Table 2 Study procedure
T0 T1
Consent x
Randomization x
Clinical examination x x
Colonic transit x
Ano-rectal manometry x
Stimulation
Constipation symptoms (diary, PAC-SYM) x
Quality of life (PAC-QOL) x
T0 pre-inclusion, T1 baseline assessment (T0 ± 15 days), T2 beginning of stimulation
(T0 ± 8 weeks), T5 follow-up at 1 month, T6 follow-up at 6 months and end of studyRecruitment and follow-up
Screening and inclusion
During a 2-week observational period, the eligible patients
will be asked to report the number of spontaneous,
complete bowel movements per week to the physicians
(partners of the study) in a bowel diary (T0). The patients
who meet all the inclusion and exclusion criteria will
be randomized into one of the two treatment groups
after completing the consent form and getting it to the
investigator.
Randomization
Computer-generated randomized lists will be drawn up
before the beginning of the study, using a permuted
block design, under the responsibility of the clinical re-
search unit (AP-HM). The randomization will be strati-
fied by center (1:1 allocation ratio). The allocation
sequences will be sequentially numbered. The pharma-
cist responsible for the medical device distribution in
the participating centers will take care of the lists. Prior
to the study period, the participant, the treating medical
staff and the investigators will all be unaware of the
allocation.
Follow-up and data collection
The evaluation will be performed at six different time
points: baseline (T1), initial visit (T2, beginning of the
stimulation), intermediary visit (T3, 4 weeks after T2),
end of stimulation (T4, 8 weeks after T2), and 1 and 6
months after the end of stimulation (T5 and T6). Min-
imal data of lost to follow-up patients will be collected
to determine whether they differ from the others. The
study procedure and data collection are detailed in
Table 2.
Endpoints/Evaluation criteria
Primary endpoint
The primary endpoint is the short-term efficacy (response
to treatment) after 8 weeks of stimulation. A subject will
be classified as a responder when he/she has three orT2 T3 T4 T5 and T6
x x x x
x
x
x x x x
x x x x
(T1 ± 15 days), T3 intermediary assessment (T0 ± 4 weeks), T4 end of stimulation
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during the 8 weeks of the trial. The primary endpoint was
chosen considering the last randomized trial on severe
chronic constipation published in the New England Journal
of Medicine [9].
Secondary endpoints
Efficacy will be assessed by the following endpoints:
– Long-term efficacy (response to treatment) at 1 (T5)
and 6 months (T6).
– Constipation symptoms will be assessed using the
Patient Assessment of Constipation Symptoms
questionnaire (PAC-SYM) [10]. This questionnaire
includes 12 constipation-related symptoms scored on
three subscales: stool, abdominal or rectal symp-
toms. For the overall scale and for each subscale,
scores can range from 0 (symptoms absent) through 4
(very severe symptoms).
– Colonic transit time will be measured according
to the Bouchoucha technique [11]. With this
technique, the subjects ingest ten markers for 6
days at regular times. A plain film of the abdomen is
performed at the 7th day. The number of persistent
markers is analyzed in each area of interest (colonic
segment). The total and segmental transit time is
calculated by multiplying the number of markers by
segment by 2.4. A slow transit time is defined by a
total transit time greater than 91.2 h for women and
76.8 h in men.
– Ano-rectal manometry will be realized according
to each center’s usual procedure. The following
parameters will be collected: resting pressure and
increment in the voluntary contraction measured in
mmHg, maximal rectal tolerable volume in ml and
presence of an anismus.
– Self-perception of the subject will be assessed using
a patient global assessment of efficacy of the
treatment based on an analogical visual scale (AVS)
from 0 (not satisfied at all) to 5 (completely satisfied).
– The patients’ quality of life will be assessed using
the Patient Assessment of Constipation Quality
of Life (PAC-QOL) questionnaire [12]. This self-
reported questionnaire includes 28 items related
to the effects of constipation on the daily life on
four subscales: physical discomfort, psychosocial
discomfort, worries and concerns, and satisfac-
tion. For each item, scores can range from 0
through 4 with lower scores indicating a better
quality of life.
– Tolerance will be analyzed from the side effects or
unexpected effect such as pain (local, ventral or
dorsal) or neurological symptom such as paresthesia,
burning and shaking.Pharmaceutical aspects
Devices (both effective or sham) and electrodes will be la-
beled and numbered according to the randomization list
and sent to the dispensing pharmacist of each investigating
center under the responsibility of the Hospital Pharmacy of
AP-HM. At the end of the study, devices will be returned
to the hospital coordinating pharmacy of the sponsor.
Statistical considerations
Sample size, power and statistical methods
The sample size was determined to obtain an 80 % power
to detect a 20 % difference in treatment response at 8
weeks between the two groups (15 % in the control
group). This difference based on previous reports [1, 3, 9]
has been considered to be clinically significant. With the
threshold for statistical significance set at a p-value of
0.05, assuming that a potential 15 % of patients will be lost
to follow-up, these calculations showed that 190 patients
are needed (95 per group). A total of 200 individuals will
be included.
Data analysis
The data will be analyzed using SPSS version 17.0 soft-
ware. The patients found to be eligible but not included
in the study will be described and compared with the in-
cluded patients. The patients who present at least one of
the following conditions will not be included in the final
analysis: patients inappropriately included despite pro-
viding consent and patients who withdrew their consent.
The full analysis population (including all subjects who
will be randomized and will be at least evaluated at T2)
will be used in the primary analysis, and the per protocol
population (including all subjects who will be random-
ized and will not have major protocol deviations) will be
used in the secondary analysis to assess the robustness
of the results. No interim analysis is planned. The normal-
ity of these parameters will be estimated using frequency
histograms and the Shapiro test. The baseline parameters
will be compared between the two groups (‘control’ and
‘experimental’) using the chi2 test or Fisher’s exact test for
categorical variables and Student’s t test for continuous
variables.
The proportion of treatment response at 8 weeks (pa-
tients with three or more spontaneous, complete bowel
movements per week) will be calculated for each group
and compared using the chi2 test or Fisher’s exact test
for categorical variables. The center effect will be tested.
The same procedure will be performed for the long-
term efficacy. PAC-SYM scores, colonic transit times,
manometric parameters, self-perception efficacy on the
AVS and PAC-QOL scores will be compared between
the two groups using Student’s test for continuous vari-
ables if applicable (or using nonparametric tests and the
Mann-Whitney test). Changes between each initial score
Vitton et al. Trials  (2015) 16:234 Page 6 of 7and the score at T3, T4, T5 and T6 will be compared be-
tween the two groups, and the analysis of variance for
repeated measurements will be performed to compare
the changes in the scores over time between the two
groups. Multivariate analysis using logistic regression
models will be performed to determine variables poten-
tially linked to treatment response. Variables relevant to
the models will be selected based on their clinical signifi-
cance and/or a threshold p-value ≤ 0.2 in the univariate
analysis. The final models will estimate the odd ratios
and 95 % confidence intervals. All of the tests will be
two-tailed with a 5 % significance level.
Ethical aspects, laws and regulations
The study will be conducted in accordance with the
Helsinki Declaration and the French laws and regula-
tions (Code de la Santé Publique, article L.1121-1/Loi de
Santé Publique n°2004-806 du 9 août 2004 relative à la
politique de santé publique et ses décrets d’application
du 27 août 2006) and the International Conference on
Harmonization (ICH) E6 Guideline for Good Clinical
Practice. Regulatory monitoring will be performed by
the sponsor. The sponsor needed the approval of the
French authorities, including the French ethics committee
(Comité de Protection des Personnes Sud Méditerranée,
reference number 14 89) and the French drug and device
regulation agency (Agence Nationale de Sécurité du
Médicament, reference number DMTCOS/DMCOSM/
SV/2014-A01359-38) before beginning the study. The
ClinicalTrials.gov identifier is NCT02381665. Informed
consent will be obtained from all subjects.
Discussion
To date, no randomized study has determined the effi-
cacy and tolerance of interferential therapy, a noninvasive
and nonpharmacological treatment, in adult patients suf-
fering from chronic constipation refractory to medical
treatment. If its effectiveness is demonstrated, it will pro-
vide, for the first time, a new noninvasive step for patients
with laxative treatment failure before considering surgi-
cal treatment. We will use a randomized, double-blind,
placebo-controlled design, which is the most appropriate
design to demonstrate the efficacy of a new experimental
intervention in accordance with the Levels of Evidence
classification of the Evidence-Based Medicine Working
Group (Oxford Centre for Evidence-Based Medicine, table
of Evidence Working Group, http://www.cebm.net/index.-
aspx?o=5653, May 26, 2015). In the future, national and
international recommendations could be updated based
on our findings.
However, some issues related to the content of the
protocol study should be discussed.
A parallel design has been adopted, although an intra-
individual crossover design is generally considered to bethe most appropriate to assess the efficacy of a new anal-
gesic strategy because of the well-known patient variation
in the subjective perception of constipation symptoms. In
the crossover study, each subject acts as his/her own con-
trol. Several limitations of crossover trials have led us to
avoid this design [13]. The crossover design is suitable for
patients in stable condition, which is not the case for pa-
tients with chronic constipation. Moreover, we suspect
that the treatment may have a remnant effect that may
alter the response to subsequent treatments inducing that
subjects may not be in a comparable condition at the start
of each treatment period. Lastly, the crossover design does
not allow the assessment of long-term efficacy.
In the current study, patients receiving the sham de-
vice will not feel any stimulation, and they will use the
device during a total time of 1 h for 8 weeks. The
sham device will be programmed in this way, and its
external aspect will not differ from the effective de-
vice. Patients with the effective stimulation will feel
the stimulation during the whole stimulation period
(1 h for 8 weeks). However, since the instructions need
to differ between the two patient groups, the practi-
tioner that will give the instructions must absolutely
differ from the one who will follow the patients. All
patients will be told that they may or may not feel
something with the stimulation because people always
respond differently to the stimulation. Because only
one practitioner will know which device is attributed
to the patient, participants will be instructed not to re-
veal or discuss the type of treatment characteristics
they are experiencing with the other practitioner. The
other option would have been to use a sham stimula-
tor inducing a short (few seconds or minutes) stimula-
tion before stopping. Our choice is supported by two
main reasons: The first reason is to be in accordance
with the literature. Indeed, a recent review of the lit-
erature on randomized controlled trials about transcu-
taneous electric nerve stimulation showed that the
majority of the studies reported using an inactive de-
vice looking identical in appearance to the active one
[14]. The second reason is supported by the physio-
logical effect of somato-sympathetic reflexes. Indeed,
some studies have demonstrated that stimulating the
skin could induce somato-visceral reflexes that can
modify visceral functions. Since these activities can be
induced by a very short stimulation, it seems that, to
be a real control, a sham stimulator should not induce
any stimulation [15–17].
Concerning the patient characteristics, the selection cri-
teria chosen are usual criteria to evaluate a new treatment
for chronic constipation defined according to the Rome
criteria. However, what can be different from some other
studies here is that we choose to include both slow transit
constipation (STC), characterized by impaired propulsion
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difficulty or inability with stool expulsion [2]. Although
the underlying mechanism is not the same, these two
types of constipation are linked. Indeed, slow transit
constipation may induce the production of dehydrated
and small hard stools that are difficult to evacuate, thus
inducing defecatory disorders. In the same manner, in
case of evacuation disorders, the ano-colonic reflex is
not correctly stimulated, and it can slow down the co-
lonic transit. According to the usual imbrication of
these two mechanisms, especially in clinical practice,
we choose to include both of these types of chronic
constipation.
The treatment procedure chosen is the same initially
described by Chase et al. in children [5]. Indeed, to our
knowledge, this team is the only one that has published
this technique with a very interesting success rate con-
firmed in a randomized study [4].
The treatment response will be assessed according to
both clinical and radiological criteria. The primary criterion
chosen is a clinical one and will be the short-term efficacy
at 8 weeks defined as the response to treatment. A subject
will be classified as a responder when he/she has three or
more spontaneous, complete bowel movements per week
during the 8 weeks of the trial. This primary end point was
chosen considering the last randomized trial on severe
chronic constipation published in the New England Journal
of Medicine [9]. To obtain a complete assessment of the
interferential therapy effect, we complement this primary
criterion with clinical and radiological efficacy endpoints.
In conclusion, the results of this randomized trial are ex-
pected to confirm that interferential therapy may be a new
noninvasive treatment in chronic constipation.
Trial status
At the time of manuscript submission, the status of the
trial was ‘not yet recruiting’.
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